CureVac (CVAC) Competitors $3.12 -0.05 (-1.58%) (As of 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CVAC vs. CPRX, HCM, ARWR, DYN, PTGX, AMRX, NAMS, LBPH, CNTA, and LGNDShould you be buying CureVac stock or one of its competitors? The main competitors of CureVac include Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Dyne Therapeutics (DYN), Protagonist Therapeutics (PTGX), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Longboard Pharmaceuticals (LBPH), Centessa Pharmaceuticals (CNTA), and Ligand Pharmaceuticals (LGND). These companies are all part of the "pharmaceutical preparations" industry. CureVac vs. Catalyst Pharmaceuticals HUTCHMED Arrowhead Pharmaceuticals Dyne Therapeutics Protagonist Therapeutics Amneal Pharmaceuticals NewAmsterdam Pharma Longboard Pharmaceuticals Centessa Pharmaceuticals Ligand Pharmaceuticals CureVac (NASDAQ:CVAC) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends. Do insiders and institutionals hold more shares of CVAC or CPRX? 17.3% of CureVac shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 11.0% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, CVAC or CPRX? Catalyst Pharmaceuticals has lower revenue, but higher earnings than CureVac. CureVac is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCureVac$543.28M1.29-$281.58M$0.555.69Catalyst Pharmaceuticals$460.48M5.46$71.41M$1.1817.86 Do analysts rate CVAC or CPRX? CureVac presently has a consensus target price of $10.00, suggesting a potential upside of 219.49%. Catalyst Pharmaceuticals has a consensus target price of $31.14, suggesting a potential upside of 47.74%. Given CureVac's higher possible upside, research analysts clearly believe CureVac is more favorable than Catalyst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Catalyst Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CVAC or CPRX? Catalyst Pharmaceuticals received 469 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 74.74% of users gave Catalyst Pharmaceuticals an outperform vote while only 54.35% of users gave CureVac an outperform vote. CompanyUnderperformOutperformCureVacOutperform Votes2554.35% Underperform Votes2145.65% Catalyst PharmaceuticalsOutperform Votes49474.74% Underperform Votes16725.26% Is CVAC or CPRX more profitable? Catalyst Pharmaceuticals has a net margin of 31.01% compared to CureVac's net margin of 20.72%. Catalyst Pharmaceuticals' return on equity of 40.79% beat CureVac's return on equity.Company Net Margins Return on Equity Return on Assets CureVac20.72% 21.98% 15.72% Catalyst Pharmaceuticals 31.01%40.79%34.87% Which has more risk & volatility, CVAC or CPRX? CureVac has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Does the media refer more to CVAC or CPRX? In the previous week, Catalyst Pharmaceuticals had 5 more articles in the media than CureVac. MarketBeat recorded 8 mentions for Catalyst Pharmaceuticals and 3 mentions for CureVac. CureVac's average media sentiment score of 1.19 beat Catalyst Pharmaceuticals' score of 1.11 indicating that CureVac is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CureVac 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Catalyst Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCatalyst Pharmaceuticals beats CureVac on 14 of the 18 factors compared between the two stocks. Ad Porter & CompanyKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks. It’s all waiting for you here. Get CureVac News Delivered to You Automatically Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVAC vs. The Competition Export to ExcelMetricCureVacPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$700.74M$6.60B$5.17B$9.03BDividend YieldN/A2.96%4.96%4.20%P/E Ratio5.6910.6887.1417.05Price / Sales1.29195.771,125.75118.75Price / CashN/A57.1543.2737.84Price / Book1.255.114.824.94Net Income-$281.58M$150.98M$120.07M$225.13M7 Day Performance5.74%1.27%1.02%3.71%1 Month Performance9.06%-6.39%16.06%2.47%1 Year Performance-25.65%6.34%28.43%17.10% CureVac Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVACCureVac4.7508 of 5 stars$3.12-1.6%$10.00+220.5%-24.7%$698.51M$543.28M5.671,172Short Interest ↓Positive NewsCPRXCatalyst Pharmaceuticals4.8839 of 5 stars$21.49+1.0%$31.14+44.9%+27.7%$2.56B$460.48M18.21167Positive NewsHCMHUTCHMED3.1781 of 5 stars$14.20-0.8%$19.00+33.8%-21.2%$2.48B$420.26M0.001,988Short Interest ↓News CoveragePositive NewsARWRArrowhead Pharmaceuticals4.5045 of 5 stars$19.75+1.5%$42.70+116.2%-38.0%$2.46B$3.55M-3.93400DYNDyne Therapeutics3.0978 of 5 stars$23.980.0%$50.42+110.2%+78.3%$2.44BN/A-6.74100Positive NewsPTGXProtagonist Therapeutics2.8763 of 5 stars$40.90-1.4%$53.78+31.5%+69.9%$2.44B$323.80M15.38125Positive NewsAMRXAmneal Pharmaceuticals3.9451 of 5 stars$7.81+0.4%$10.00+28.0%+28.8%$2.42B$2.68B-11.497,700Short Interest ↓NAMSNewAmsterdam Pharma3.0549 of 5 stars$25.60+0.4%$36.20+41.4%+131.5%$2.37B$33.59M0.0057Analyst ForecastLBPHLongboard Pharmaceuticals0.7252 of 5 stars$59.98+0.0%$59.56-0.7%+894.7%$2.34BN/A-26.9020CNTACentessa Pharmaceuticals2.8377 of 5 stars$17.36+1.2%$25.83+48.8%+112.9%$2.29B$6.85M-11.3572Short Interest ↑LGNDLigand Pharmaceuticals4.9596 of 5 stars$115.99+1.2%$147.00+26.7%+52.9%$2.19B$152.42M46.2180 Related Companies and Tools Related Companies CPRX Competitors HCM Competitors ARWR Competitors DYN Competitors PTGX Competitors AMRX Competitors NAMS Competitors LBPH Competitors CNTA Competitors LGND Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CVAC) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
